Game changing' data: New obesity drugs tied to major weight loss, may reduce CV risk Survodutide PeptiFy Labs What is cagrisema and how does it work for weight loss? Dual and Triple Gut Peptide Agonists on the Horizon for the Treatment of Type 2 Diabetes and Obesity. An Overview of Preclinical and Clinical Data Current Obesity Reports Springer Nature Link Emerging Trends in the Development of GLP 1 Receptor Agonists Biopharma PEG In Chinese adults with overweight or obesity, once weekly #GLP glucagon agonist mazdutide, at a dose of 4 mg or 6 mg for 32 48 weeks, led to clinically relevant #weightloss in the